Meeting
2014 Gastrointestinal Cancers Symposium
Prognostic and predictive blood-based biomarkers of overall survival (OS) in patients (pts) with advanced colorectal cancer (CRC) treated with cetuximab (C): Results from CALGB 80203 (Alliance).
Authors
Ace J. Hatch
Duke University Medical Center, Durham, NC
Ace J. Hatch , Herbert Pang , Mark D. Starr , John C. Brady , Jingquan Jia , Donna Niedzwiecki , Alan Paul Venook , Stephanie M. Cushman , Herbert Hurwitz , Andrew B. Nixon
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
General Poster Session C: Cancers of the Colon and Rectum
Track
Cancers of the Colon, Rectum, and Anus
Sub Track
Translational Research
Citation
J Clin Oncol 32, 2014 (suppl 3; abstr 448)
DOI
10.1200/jco.2014.32.3_suppl.448
Abstract #
448
Poster Bd #
B11
Abstract Disclosures
Similar Posters
Poster
2014 ASCO Annual Meeting
Prognostic and predictive blood-based biomarkers of overall survival (OS) in patients (pts) with advanced colorectal cancer (CRC) treated with cetuximab (C): Results from CALGB 80203 (Alliance).
First Author: Ace Joseph Hatch
Poster
2019 Gastrointestinal Cancers Symposium
On-treatment changes of plasma protein biomarkers in CALGB/SWOG 80405 (Alliance).
First Author: Ace Joseph Hatch
Poster
2012 Markers in Cancer
Use of epiregulin (EREG) and amphiregulin (AREG) gene expression to predict response to cetuximab (cet) in combination with oxaliplatin (Ox) and 5FU in the first-line treatment of advanced colorectal cancer (aCRC).
First Author: Richard Adams
Poster
2012 ASCO Annual Meeting
Mutant (MT) KRAS codon 12 and 13 alleles in patients (pts) with metastatic colorectal cancer (mCRC): Assessment as prognostic and predictive biomarkers of response to panitumumab (pmab).
First Author: Marc Peeters